PORTFOLIO NEWS Nura Bio (formerly Proneurotech) Launches to Discover and Develop Neuroprotective Drugs, Backed by $73M Series A Financing July 29, 2020 Read More » NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) July 27, 2020 Read More » Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering July 23, 2020 Read More » Circle Pharma Appoints Rajinder Singh, PhD as its Chief Science Officer July 20, 2020 Read More » Arcus Biosciences and Gilead Sciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies July 13, 2020 Read More » Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock July 8, 2020 Read More » Arcus Biosciences Appoints Bob Goeltz as Chief Financial Officer July 7, 2020 Read More » Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor June 22, 2020 Read More » Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials June 19, 2020 Read More » Rapt Therapeutics Appoints Peter Svennilson to Board of Directors June 18, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Next »
Nura Bio (formerly Proneurotech) Launches to Discover and Develop Neuroprotective Drugs, Backed by $73M Series A Financing July 29, 2020 Read More »
NGM Bio Announces Initiation of Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) July 27, 2020 Read More »
Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering July 23, 2020 Read More »
Arcus Biosciences and Gilead Sciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies July 13, 2020 Read More »
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock July 8, 2020 Read More »
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor June 22, 2020 Read More »
Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials June 19, 2020 Read More »
